The global market for drug-induced dyskinesia is witnessing remarkable growth, according to the latest market analysis. Projections indicate a trajectory leading to a notable milestone of USD 399.8 million by fiscal year 2023, with further anticipated growth to USD 620.2 million by 2033.
The findings, based on comprehensive market research, reveal a compound annual growth rate (CAGR) of 4.25%. This steady expansion underscores the increasing demand for effective treatments in managing drug-induced dyskinesia, a condition characterized by involuntary movements typically resulting from prolonged medication use.
Request A Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-16150
However, the market is expected to face certain challenges, including:
- Adverse effects of medications: Some medications used to treat drug-induced dyskinesia can cause side effects such as clonidine-induced hypotension and sedation, which may limit their use.
- High treatment costs: The cost of treatment for drug-induced dyskinesia can be high, which may limit access to care for some patients.
- Poor diagnosis rates: Dyskinesia can sometimes be difficult to diagnose, which can delay treatment and worsen symptoms.
- Societal stigma: There may be a stigma associated with dyskinesia, which can prevent people from seeking treatment.
- Shortage of qualified healthcare professionals: There is a shortage of qualified healthcare professionals with expertise in treating dyskinesia, which can limit access to care.
- High cost of clinical trials: The high cost of conducting clinical trials for new treatments for drug-induced dyskinesia can hamper the development of new therapies.
Despite these challenges, the market is expected to grow due to the increasing demand for effective treatments for drug-induced dyskinesia. There is ongoing research and development of new therapies with the potential to overcome the limitations of existing options.
Key Takeaways from the Market Study:
- The global drug-induced dyskinesia industry is currently worth more than USD 382 Million.
- In 2023, the VMAT 2 segment by drug class is expected to take the dominant market share of 46%.
- In 2023, considering the end-user type, the hospitals segment is predicted to gain a 32% market share.
- The North American market for drug-induced dyskinesia is predicted to grow with a steady CAGR of 4.3% from 2023-2033.
- The APAC for drug-induced dyskinesia is expected to grow with a steady CAGR of 3.5% during 2023-2033.
“During the next ten years, the market for drug-induced dyskinesia will grow robustly owing to increasing neuroleptic patients and rising elderly population.” comments a Future Market Insights analyst.
Ask for Customize Research Report: https://www.futuremarketinsights.com/customization-available/rep-gb-16150
Competitive Landscape:
- Teva Pharmaceuticals
- Neurocrine Bioscience
- Sun Pharmaceutical Industries Ltd
- SteriMax Inc.
- Lannett Co Inc
- Adamas Pharmaceuticals, Inc
- Sanis
- AbbVie Inc.
- Dystonia Medical Research Foundation
- Pharos: Illuminating the Druggable Genome
Some Notable Advancements In The Global Market For Drug-Induced Dyskinesia Are:
At the American Mental Association Annual Meeting in May 2022, Neurocrine Biosciences presented different INGREZZA (valbenazine) findings on drug-induced dyskinesia improvements and stabilization of psychiatric symptoms.
The study discovered that long-term (48-week) care with once-daily INGREZZA (40 mg or 80 mg) led to significant clinician-rated as well as self-rated global advancements of drug-induced dyskinesia symptoms while maintaining psychiatric symptom consistency, regardless of the patient’s primary psychological condition.
In March 2022, Neurocrine Bioscience and Mitsubishi Tanabe Pharma Corporation shared the news that DYSVAL (Valbenazine), a medication used to treat drug-induced dyskinesia, has been given regulatory clearance in Japan.
According to their agreement, Neurocrine Biosciences will be entitled to royalty payments at scaled percentages on MTPC’s prospective net sales of valbenazine in Japan as well as other specified Asian markets. Mitsubishi Tanabe Pharma Corporation will be liable for all costs associated with the development, manufacturing, and commercialization of valbenazine.
Key Segments Covered In The Drug-induced dyskinesia industry Report:
Drug-Induced Dyskinesia Market by Drug Class:
- Dopamine-Depleting Medications
- Vmat2 Inhibitors
- Gaba Receptor Agonist Medications
- Anticholinergic Medications
Drug-Induced Dyskinesia Market by End User:
- Hospitals
- Clinics
- Others
Drug-Induced Dyskinesia Market by Region:
- North America
- Latin America
- Europe
- Asia-Pacific (APAC)
- Middle East & Africa (MEA)
A Comprehensive Full Report: https://www.futuremarketinsights.com/checkout/16150
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
